Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of PRRT4 (proline rich transmembrane protein 4) cell factor in preparation of drugs to treat hepatic failure

A liver failure, cytokine technology, applied in the fields of clinical medicine, molecular medicine and biomedicine

Inactive Publication Date: 2019-09-06
ZHEJIANG UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Polyproline transmembrane protein 4 (PRRT4) is a member of the polyproline transmembrane protein family. At present, there are few reports on the association between PRRT4 and diseases, and it may only be related to peripheral edema in diabetes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of PRRT4 (proline rich transmembrane protein 4) cell factor in preparation of drugs to treat hepatic failure
  • Application of PRRT4 (proline rich transmembrane protein 4) cell factor in preparation of drugs to treat hepatic failure
  • Application of PRRT4 (proline rich transmembrane protein 4) cell factor in preparation of drugs to treat hepatic failure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Embodiment 1: Injection containing PRRT4 cytokines treats a large animal (young pig) model of liver failure

[0043] Animal model: 30 male Chinese young pigs (8-10 kg) were randomly divided into two groups, 15 in each group. Each young pig was injected with D-gal 1.5g / kg in the jugular vein to create a liver failure model.

[0044] Test group: Multiple intravenous injections of PRRT4 injection at fixed time points after D-gal injection, dose: 10ml / kg, twice a day.

[0045] Control group: inject the same amount of normal saline without PRRT4.

[0046] Neither the control group nor the experimental group received other drug treatment.

[0047] figure 1 It is a schematic diagram of the survival time curves of the young pigs of the experimental group and the control group, showing the survival rate of the young pigs of the experimental group and the control group. The results showed that the 3-day survival rate of young pigs in the treatment group containing PRRT4 cytok...

Embodiment 2

[0048] Example 2: The small animal (rat) model of liver failure treated by lyophilized powder injection containing PRRT4 cytokine

[0049] Animal model: 100 male rats (200-250 g) were randomly divided into two groups, 50 in each group. Each rat was intraperitoneally injected with D-gal 1.5g / kg to make a liver failure model. The PRRT4 lyophilized powder and water for injection are prepared into a suspension.

[0050] Experimental group: 4 ml of PRRT4 lyophilized powder suspension was injected intraperitoneally at a fixed time point after D-gal injection, twice a day.

[0051] Control group: inject the same amount of normal saline without PRRT4.

[0052] Both the control group and the experimental group received no other drug treatment.

[0053] figure 2 Schematic diagram of the survival time curves of rats in the experimental group and the control group, figure 2 The survival rates of the rats in the experimental group and the control group were shown: the results showed...

Embodiment 3

[0054] Embodiment 3: The suspension containing PRRT4 cytokine treats the rabbit model of hepatic failure

[0055]Animal model: 40 adult male rabbits (2000-2500 g) were randomly divided into two groups, 20 in each group. Each rabbit was intramuscularly injected with D-gal 1.5g / kg to make a liver failure model.

[0056] Experimental group: intramuscular injection of 20 ml of PRRT4 suspension at a fixed time point after D-gal injection, twice a day.

[0057] Control group: inject the same amount of normal saline without PRRT4.

[0058] Both the control group and the experimental group received no other drug treatment.

[0059] image 3 It is a schematic diagram of the survival time curves of rabbits in the experimental group and the control group, image 3 The survival rate of the rabbits in the experimental group and the control group is shown: the results show that the survival rate of the rabbits in the PRRT4 treatment group is 90% at 1 day and 80% at 7 days, while the sur...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a PRRT4 (proline rich transmembrane protein 4) cell factor in the preparation of drugs to treat hepatic failure. The drugs include PRRT4 cell factor pharmaceutically-acceptable excipients, antioxidants and vectors. The course of hepatic failure is involved with severe metabolic disorders, especially lipidosis. PRRT4 cell factor can overcome the difficulty; PRRT4 is associated with the functionality of mesenchymal stem cells and can promote the treatment of liver healing. In the application in the preparation of drugs to treat hepatic failure, PRRT4 cell factor can evidently increase biochemical indexes of a patient, lower bilirubin level, reduce aminotransferase, improve the coagulation function, increase the albumin level, inhibit apoptosis of hepatic cells, promote the regeneration of hepatic cells and bile tube cells, prevent fatal complications, such as upper gastrointestinal bleeding, severe hepatic encephalopathy and hepatorenal syndrome, evidently extend the survival time, and increase the survival rate.

Description

technical field [0001] The invention belongs to the fields of clinical medicine, molecular medicine and biomedicine, and is a new technology for treating liver failure with PRRT4 cytokine series drugs, specifically, an application of PRRT4 cytokine in the preparation of medicaments for treating liver failure. Background technique [0002] Liver failure is a kind of disease caused by extensive necrosis of the liver caused by various reasons. Except for orthotopic liver transplantation, there is currently no specific treatment. However, due to the severe shortage of donor livers, a large number of patients died while waiting for liver transplantation. Clarifying the pathogenesis of liver failure and early treatment targeting the mechanism can effectively block the progression of the disease and reduce the mortality rate, which is of great significance to the treatment of liver failure. [0003] Polyproline transmembrane protein 4 (PRRT4) is a member of the polyproline transm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/19A61P1/16
CPCA61K38/19A61P1/16
Inventor 李君陈新李江梁茜李佳琪辛娇娇
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com